Human dual-specificity phosphatase 7 (DUSP7/Pyst2) is a 320-residue protein that belongs to the mitogen-activated protein kinase phosphatase (MKP) subfamily of dual-specificity phosphatases. Although its precise biological function is still not fully understood, previous reports have demonstrated that DUSP7 is overexpressed in myeloid leukemia and other malignancies. Therefore, there is interest in developing DUSP7 inhibitors as potential therapeutic agents, especially for cancer. Here, the purification, crystallization and structure determination of the catalytic domain of DUSP7 (Ser141-Ser289/ C232S) at 1.67 Å resolution are reported. The structure described here provides a starting point for structure-assisted inhibitor-design efforts and adds to the growing knowledge base of three-dimensional structures of the dual-specificity phosphatase family.
Introduction
The dual-specificity phosphatases (DUSPs) constitute a group of protein tyrosine phosphatases (PTPs) that are characterized by their ability to dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues (Patterson et al., 2009) . Within the DUSP family, the mitogen-activated protein kinase phosphatases (MKPs) represent an additional subgroup (Farooq & Zhou, 2004) . MKPs contain two main domains: a conserved C-terminal catalytic domain that harbors the active site where the dephosphorylation reaction occurs (Yuvaniyama et al., 1996; Stewart et al., 1999) and an Nterminal rhodanese-like domain that functions as a mitogenactivated protein kinase (MAPK)-binding domain (Farooq & Zhou, 2004; Zhang et al., 2011) . The 320-residue human dualspecificity phosphatase 7 (DUSP7/Pyst2) is a cytosolic MKP that dephosphorylates the extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK) and p38 kinase (Dowd et al., 1998; Orlev et al., 2004) . Although not thoroughly characterized in the literature, DUSP7 has been shown to be overexpressed in peripheral blood mononuclear cells and bone marrow from patients diagnosed with acute leukemia (Levy-Nissenbaum, Sagi-Assif, Kapon et al., 2003; Levy-Nissenbaum, Sagi-Assif, Raanani et al., 2003a,b) . Consequently, it has been suggested that the development of DUSP7 inhibitors may have potential therapeutic utility in the treatment of cancer (Nunes-Xavier et al., 2011) . Other studies have suggested, however, that DUSP7 may function as a tumor suppressor (Shin et al., 1997) . Therefore, DUSP7 inhibitors may be beneficial for the treatment of some forms of cancer but contraindicated for others. Animal studies examining the effects of DUSP7 deletions or 'knock-downs' and specific small-molecule inhibitors are needed to further characterize the function and therapeutic potential of DUSP7.
Although the field of protein tyrosine phosphatase drug discovery has yet to attain the level of success that has been achieved with protein kinase inhibitors, there remains significant interest in the direct inhibition of PTPs as a means of designing novel therapeutics (Ríos et al., 2014; He et al., 2014) . The successful identification of DUSP inhibitors for progression to drug candidates, however, presents many difficult obstacles for a number of reasons (Blaskovich, 2009) . In particular, the DUSP active site is usually rather shallow, a feature that is necessary for the accommodation of both phosphotyrosine and phosphoserine/phosphothreonine residues (Yuvaniyama et al., 1996; Schumacher et al., 2002) . Additionally, the active-site pocket, which is formed by the consensus sequence (H/V)C(X 5 )R(S/T) (Zhang et al., 1994; , is highly conserved and exhibits a preference for negatively charged compounds which often have limited specificity, cell permeability and bioavailability. Therefore, in addition to targeting the active site of PTPs and DUSPs, an alternative approach has been to target secondary sites that extend beyond the catalytic pocket in order to achieve increased binding affinity and greater specificity (Puius et al., 1997; Bahta et al., 2011) . This strategy has been greatly aided by the availability of high-resolution crystal structures that have facilitated the rational design of such bidentate or multidentate inhibitors (Sun et al., 2003; Wu et al., 2009; Kim et al., 2011; Bahta et al., 2011) . To date, only a few DUSP7 inhibitors have been identified using virtual screening methods and a homology model of DUSP7 . Here, we present the crystal structure of the catalytic domain of DUSP7 (C232S) at 1.67 Å resolution, which provides a structural template that may be used to advance the development of DUSP7 inhibitors.
Materials and methods

Cloning, expression and purification of DUSP7
Efforts to crystallize the wild-type DUSP7 catalytic domain were unsuccessful. Therefore, we chose to work with a catalytically inactive form of the protein harboring the active-site C232S mutation. The catalytic domain of DUSP7 (Ser141-Ser289) was amplified from DNASU clone HsCD00434660 by the polymerase chain reaction (PCR) using the following oligodeoxyribonucleotide primers: 5 0 -GAG AAC CTG TAC TTC CAG AGC CAA CCA GCC TTC CCT GTC CAG ATC CTG CCC-3 0 and 5 0 -G GGG ACC ACT TTG TAC AAG AAA GCT GGG TTA GCT TAG CCC CAG CGT CCG CTC-3 0 (primer 2). The PCR product was used as the template for a second PCR amplification with primer: 5 0 -GGGG ACA AGT TTG TAC AAA AAA GCA GGC TCG GAG AAC CTG TAC TTC CAG GGT-3 0 and primer 2. The amplicon from the second round of PCR, coding for DUSP7 (Ser141-Ser289) with an N-terminal tobacco etch virus (TEV) protease cleavage site (ENLYFQ/G), was recombined into the donor vector pDONR221 (Life Technologies, Grand Island, New York, USA) to generate the entry clone pBA2408 and its nucleotide sequence was verified. The C232S mutation in DUSP7 was introduced by QuikChange Lightning sitedirected mutagenesis (Agilent, Santa Clara, California, USA) using primers 5 0 -GGT GTC CTG GTG CAC TCC CTG GCA GGC ATC AGC C-3 0 and 5 0 -GGC TGA TGC CTG CCA GGG AGT GCA CCA GGA CAC C-3 0 , yielding pBA2528. The C232S variant was then recombined from pBA2528 into pDEST-HisMBP (Nallamsetty et al., 2005; Tropea et al., 2009) to generate the expression vector pBA2529. The latter plasmid produces a His 6 -MBP-DUSP7 (Ser141-Ser289/C232S) fusion protein that can be cleaved by TEV protease to give rise to DUSP7 PTP domain consisting of residues Ser141-Ser289 and containing the C232S amino-acid substitution.
The fusion protein was produced in Escherichia coli strain BL21-CodonPlus (DE3)-RIL (Agilent Technologies, La Jolla, California, USA). Cultures were grown to mid-log phase (OD 600 = 0.4-0.6) at 310 K in Luria broth supplemented with 100 mg ml À1 ampicillin, 30 mg ml À1 chloramphenicol and 0.2% glucose. Recombinant protein production was induced with isopropyl -d-1-thiogalactopyranoside at a concentration of 1 mM for 4 h at 303 K. The cells were pelleted by centrifugation and stored at 193 K.
All purification steps were carried out at 277 K. 20-25 g of E. coli cell paste was suspended in 200 ml ice-cold 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 30 mM imidazole buffer (lysis buffer). The cells were lysed by three passes through an APV-1000 homogenizer (Invensys APV Products, Albertslund, Denmark) at 69 MPa and centrifuged at 30 000g for 30 min. The supernatant was filtered through a 0.45 mm cellulose acetate membrane and applied onto a 20 ml HisPrep column (GE Healthcare, Piscataway, New Jersey) equilibrated in lysis buffer. The column was washed to baseline with lysis buffer and the protein was eluted with a linear gradient from 30 to 250 mM imidazole. Fractions containing the fusion protein were pooled and concentrated with an Amicon stirred cell equipped with a YM30 membrane (EMD Millipore, Billerica, Massachusetts, USA). The fusion protein was digested overnight with polyhistidine-tagged TEV protease (Kapust et al., 2001) . The digest was diluted with 50 mM Tris-HCl pH 7.5, 150 mM NaCl to reduce the imidazole concentration to approximately 30 mM and applied onto a 20 ml HisPrep column equilibrated with lysis buffer. DUSP7 (Ser141-Ser289/ C232S) was isolated in the column flowthrough and was concentrated using an Amicon stirred cell with a YM10 membrane. Dithiothreitol was added to the protein to a final concentration of 10 mM and the solution was allowed to incubate overnight. The sample was clarified by centrifugation, filtered through a 0.22 mm membrane and applied onto a HiPrep 26/60 Sephacryl S-100 HR column (GE Healthcare) equilibrated with 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine buffer. Peak fractions were pooled and concentrated to 20.3 mg ml À1 (estimated at 280 nm using a molar extinction coefficient of 15 930 M À1 cm À1 ). Aliquots were flash-frozen with liquid nitrogen and stored at 193 K prior to crystallization. The molecular weight was confirmed by electrospray ionization mass spectrometry.
Crystallization, data collection and structure determination
Initial crystallization screens were set up using the Gryphon crystallization robot (Art Robbins, Sunnyvale, California, USA). Sitting-drop vapor-diffusion experiments were conducted using IntelliPlates (Art Robbins) incubated at 292 K. Various protein-to-well-solution ratios were set up (1:1, 1:3 and 3:1) at a protein concentration of 20.3 mg ml À1 using the Morpheus crystallization screen (Molecular Dimensions, Altamonte Springs, Florida, USA; Gorrec, 2009) . Crystals were only obtained in condition No. 32, which consisted of 0.1 M Buffer System 2 (HEPES/MOPS pH 7.5), 0.09 M nitrate-phosphate-sulfate mixture, 37.5%(v/v) 2-methyl-2,4pentanediol-polyethylene glycol 1000-polyethylene glycol 3350. Crystals appeared within a span of 7 d. A single crystal was retrieved directly from the crystallization drop using a LithoLoop (Molecular Dimensions) and was flash-cooled by plunging it into liquid nitrogen without any additional cryoprotectant.
X-ray diffraction data were collected remotely on SER-CAT beamline 22-BM of the Advanced Photon Source, Argonne National Laboratory using a MAR 225 CCD detector. A data set from a single crystal was collected using an X-ray wavelength of 1.0 Å , an oscillation angle of 1.0 , a crystal-to-detector distance of 150 mm and an X-ray exposure per image of 1 s. Diffraction data were processed with HKL-3000 (Minor et al., 2006) . Data-collection and refinement statistics are presented in Table 1 . Initial phases were obtained by molecular replacement with MOLREP (Vagin & Teplyakov, 2010) from the CCP4 suite of programs (Winn et al., 2011) , using the structure of DUSP9/MKP-4 (PDB entry 3lj8; 78% sequence identity; Jeong et al., 2011 ) as a search model after stripping away all non-protein atoms from the model and replacing non-identical residues with alanine. Based on the Matthews coefficient of 2.3 Å 3 Da À1 and solvent content of 46.8%, the asymmetric unit was estimated to contain four molecules (Kantardjieff & Rupp, 2003; Matthews, 1968) . Model rebuilding and refinement were conducted with Coot (Emsley et al., 2010) and REFMAC5 (Murshudov et al., 2011) using A -weighted electron-density maps (Read, 1997) . Water molecules were located using ARP/wARP (Langer et al., 2008) , manually inspected and refined with REFMAC5. Model validation was performed with MolProbity (Chen et al., 2010) . The coordinates and structure-factor files were deposited in the Protein Data Bank with accession code 4y2e. Structural homologs were identified using the PDBeFold server (Krissinel & Henrick, 2004 ) and structural alignments were performed using PDEeFold and PyMOL (v.1.5.0.4; Schrö dinger).
Results and discussion
Overall structure
The structure of DUSP7 (Ser141-Ser289/C232S) was refined to a resolution of 1.67 Å with a final working R factor of 15.5% and an R free of 18.9%. Structure validation using MolProbity indicates that 96.8% of the residues are located in the Ramachandran favored regions, with no residues flagged as outliers. Four molecules were located in the asymmetric unit, all of which share very similar structures (average r.m.s.d. of $0.2 Å over 140 C -atom pairs). Analysis of the protein interfaces between molecules in the asymmetric unit using the PDBePISA server suggests that DUSP7 exists as a monomer in solution (Krissinel & Henrick, 2007) which correlates with the gel-filtration chromatographic profile (data not shown). Chain A was selected for structural description. The catalytic domain of DUSP7 consists of a central five-stranded -sheet that is surrounded by six -helices (Fig. 1a) . A phosphate ion occupies the active site that is formed by the phosphatebinding loop (residues 231-238) positioned between -strand 5 and helix 4. The general acid loop (D loop in DUSPs or WPD loop in the classical PTPs), located between helix 3 and -strand 4, adopts a closed conformation.
A search for related structures using the PDBeFold server identified the two closest structural homologs as slingshot Jeong et al., 2011) . The superimposed structures of DUSP7 and DUSP6 reveal that the major difference between the two structures is the presence of an extra -strand between -strand 4 and helix 3 in DUSP6 as a result of an outward movement of the connecting loop (Fig. 1b) . The electron density for the loop between strand 4 and helix 3 is well defined in DUSP7 (Fig.  1c ). This loop-to-strand conformational switch is found in the structures of DUSP2, DUSP6 and DUSP9 and was predicted to also exist in DUSP7 (Stewart et al., 1999; Farooq et al., 2003; Jeong et al., 2011 Jeong et al., , 2014 . Proposed to be flexible, this region in DUSP6 and DUSP9 has been postulated to participate in MAP kinase binding interactions. The crystal structures of the DUSPs that contain this extra -strand also reveal that the D loop adopts an open conformation, leading to a low-activity conformation of the catalytic domain (Jeong et al., 2014) . In the structure of DUSP7, we do not observe such a loop-tostrand switch for the loop found between -strand 4 and helix 3, likely owing to the closed conformation of the D loop. This loop is also involved in crystal contacts with neighboring symmetry mates in the crystal, which may prevent the switch to a -strand conformation.
Active site
The active site contains a phosphate ion that provides a snapshot of the structural interactions with active-site residues (Fig. 2a) . The phosphate is held in place by several hydrogen bonds between the phosphate O atoms and the backbone amide N atoms of Leu233 (3.1 Å ), Ala234 (3.0 Å ), Gly235 (3.2 Å ), Ile236 (2.9 Å ), Ser237 (3.0 Å ) and Arg238 (2.8 Å ) (Fig. 2b) . Additional hydrogen bonds are formed between the phosphate O2 atom and the Arg238 N "2 (2.8 Å ) and NH2 (2.9 Å ) N atoms. The Arg238 side chain forms a cradle-like structure around the active site that contributes a favorable positive charge to stabilize the negative charge of the phosphate ion. The side-chain O atom of Ser232 (cysteine in the wild-type enzyme) is located about 3.4 Å from the phosphate P atom, indicating that the residue occupies an appropriate position to function as the catalytic nucleophile (Zhou et al., 1994) . The side chain of the conserved Asp201 residue in the D loop (residues 197-208) points towards the active-site pocket, enabling it to form a hydrogen bond between the sidechain carboxylate O 2 atom and the phosphate O3 atom (2.6 Å ). As a result, the D loop adopts a closed conformation that primes the active site for catalysis. Because Asp201 functions as a general acid/base residue during the dephosphorylation reaction, its proper positioning with respect to the substrate is important for efficient catalysis . Substrate binding induces a conformational change from the open to the closed form of the D loop (Schubert et al., 1995) . In contrast, the side chains of the analogous Asp262 and Asp259 residues in DUSP6 and DUSP9, respectively, point away from the active site, resulting in an open conformation of the D loop (Stewart et al., 1999; Jeong et al., 2011) . The superimposed structures of DUSP7 and DUSP6 reveal significant deviations between the conformations of their phosphate-binding loops, suggesting that the active sites in DUSP6 and DUSP9 are not oriented optimally for efficient catalysis (Fig. 1b) . Indeed, the isolated catalytic domain of DUSP9 was reported to exhibit low catalytic activity (Jeong et al., 2011) .
Analysis of the surface features surrounding the active-site region of DUSP7 reveals a relatively smooth surface with very few significant indentations or neighboring pockets (Fig. 3) . This, of course, poses a challenge for the design of multidentate and other inhibitors in general. There is a small positively charged pocket directly above the active-site pocket next to the Arg238 residue. To the left of the active site and directly below the Asp201 residue, there is a small negatively charged groove. A recent survey of DUSP structures has shown that surface features in the vicinity of the active-site pockets are variable (Jeong et al., 2014) 
Figure 3
The DUSP7 catalytic domain as viewed facing the active-site region with the electrostatic surface potentials mapped onto the surface. Positive charge is colored blue, negative charge red and hydrophobic regions gray.
to exploit these small differences to achieve some degree of inhibitor specificity.
Conclusions
In summary, we have determined the crystal structure of the C-terminal catalytic domain of DUSP7 (Ser141-Ser289/ C232S) at a resolution of 1.67 Å , which adds to the growing structural knowledge base of DUSP family members. The structure is of particular interest because DUSP7 has been proposed as a drug target for certain malignancies such as leukemia. DUSP7 adopts the canonical catalytic domain fold common to many dual-specificity phosphatases but, interestingly, it differs structurally from related Pyst-type DUSPs in that it lacks an additional -strand between strand 4 and helix 3 and its D loop is observed in the closed conformation. The relatively smooth surfaces adjacent to the active-site pocket underscore the challenges of designing dual-specificity phosphatase inhibitors. It remains to be seen whether differences in surface features near the active sites of DUSP family members will be sufficient to obtain specific inhibitors.
